Navigation

Acute coronary syndrome - prasugrel with PCI (review TA182) [ID 648]

Prasugrel with percutaneous coronary intervention for treating acute coronary syndrome (review of TA182)

Status: In development
Expected date of issue: August 2014
Process: MTA
Topic area:
 

NICE project team

Technical Lead: Helen Tucker
Communications manager: Phil Ranson
Project manager:

Nicole Fisher

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 10 September 2013
1st appraisal committee meeting: 05 March 2014
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Lilly UK (prasugrel)

Patient/carer groups

  • Pumping Marvellous Foundation
  • South Asian Health Foundation

Professional groups

  • British Cardiovascular Intervention Society
  • British Heart Foundation
  • Royal College of Nursing
  • Royal College of Physicians

Others

  • Department of Health
  • NHS Fylde & Wyre CCG
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Medicines and Healthcare products Regulatory Agency

Comparator manufacturers

  • Actavis (aspirin, clopidogrel) (Confidentiality agreement not signed, not participating)
  • Aspire Pharma (clopidogrel)  (Confidentiality agreement not signed, not participating)
  • AstraZeneca (Ticagrelor)
  • Boehinringer Ingelheim (aspirin)(Confidentiality agreement not signed, not participating)
  • Beacon Pharmaceutical (clopidogrel) (Confidentiality agreement not signed, not participating)
  • Consilient Health (clopidogrel)(Confidentiality agreement not signed, not participating)
  • GlaxoSmithKline (aspirin) (Confidentiality agreement not signed, not participating)
  • Intrapharm Laboratories (aspirin) (Confidentiality agreement not signed, not participating)  
  • Pfizer (aspirin) (Confidentiality agreement not signed, not participating)
  • Reckitt Benckiser (aspirin) (Confidentiality agreement not signed, not participating)
  • Sandoz (aspirin, clopidogrel) (Confidentiality agreement not signed, not participating)
  • Sanofi (clopidogrel) (Confidentiality agreement not signed, not participating)
  • Teva UK (aspirin, clopidogrel)(Confidentiality agreement not signed, not participating)
  • The Boots Company (aspirin)(Confidentiality agreement not signed, not participating)
  • Thornton & Ross (aspirin) (Confidentiality agreement not signed, not participating)
  • Wockhardt UK (aspirin, clopidogrel)(Confidentiality agreement not signed, not participating)

Relevant research groups

  • None

Assessment Group

  • Liverpool Reviews and Implementation Group
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Key documents

This page was last updated: 28 March 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.